Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
Identifieur interne : 000133 ( Istex/Corpus ); précédent : 000132; suivant : 000134Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
Auteurs : Zhan Zhang ; Yi-Wu Xie ; Jiling Hong ; Xin Zhang ; Sui Yi Kwok ; Xiaowu Huang ; Sai Wah Wong ; Bing-Lou WongSource :
- Transfusion [ 0041-1132 ] ; 2005-07.
English descriptors
- Teeft :
- Abnormal toxicity, Assay, Biologics, Chinese requirements, Convalescent, Convalescent plasma, Dimer, Elisa, Ethanol, Ethanol precipitation, Globulin, Heat stability, Hong kong, Human sars hyperimmune globulins, Hyperimmune, Hyperimmune globulins, Ivig, July, Neutralizing, Neutralizing antibody test, Precipitation, Respiratory syndrome, Sars, Sars antibody titer, Sars convalescent plasma, Sars hyperimmune globulins, Sars virus, Syndrome, Titer, Titer recovery, Tnbp, Transfusion, Transfusion volume, Triton, Wong, Zhang.
Abstract
BACKGROUND: Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study. STUDY DESIGN AND METHODS: A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety. RESULTS: The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products. CONCLUSION: IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.
Url:
DOI: 10.1111/j.1537-2995.2005.00179.x
Links to Exploration step
ISTEX:A47B08754BF85061FDA2527E3FE9DDD27615D1F2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><author><name sortKey="Zhang, Zhan" sort="Zhang, Zhan" uniqKey="Zhang Z" first="Zhan" last="Zhang">Zhan Zhang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Xie, Yi U" sort="Xie, Yi U" uniqKey="Xie Y" first="Yi-Wu" last="Xie">Yi-Wu Xie</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Hong, Jiling" sort="Hong, Jiling" uniqKey="Hong J" first="Jiling" last="Hong">Jiling Hong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Zhang, Xin" sort="Zhang, Xin" uniqKey="Zhang X" first="Xin" last="Zhang">Xin Zhang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Kwok, Sui Yi" sort="Kwok, Sui Yi" uniqKey="Kwok S" first="Sui Yi" last="Kwok">Sui Yi Kwok</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Huang, Xiaowu" sort="Huang, Xiaowu" uniqKey="Huang X" first="Xiaowu" last="Huang">Xiaowu Huang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Wong, Sai Wah" sort="Wong, Sai Wah" uniqKey="Wong S" first="Sai Wah" last="Wong">Sai Wah Wong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Wong, Bing Ou" sort="Wong, Bing Ou" uniqKey="Wong B" first="Bing-Lou" last="Wong">Bing-Lou Wong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: blwong@advantekAB. com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A47B08754BF85061FDA2527E3FE9DDD27615D1F2</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1111/j.1537-2995.2005.00179.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000133</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000133</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><author><name sortKey="Zhang, Zhan" sort="Zhang, Zhan" uniqKey="Zhang Z" first="Zhan" last="Zhang">Zhan Zhang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Xie, Yi U" sort="Xie, Yi U" uniqKey="Xie Y" first="Yi-Wu" last="Xie">Yi-Wu Xie</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Hong, Jiling" sort="Hong, Jiling" uniqKey="Hong J" first="Jiling" last="Hong">Jiling Hong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Zhang, Xin" sort="Zhang, Xin" uniqKey="Zhang X" first="Xin" last="Zhang">Xin Zhang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Kwok, Sui Yi" sort="Kwok, Sui Yi" uniqKey="Kwok S" first="Sui Yi" last="Kwok">Sui Yi Kwok</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Huang, Xiaowu" sort="Huang, Xiaowu" uniqKey="Huang X" first="Xiaowu" last="Huang">Xiaowu Huang</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Wong, Sai Wah" sort="Wong, Sai Wah" uniqKey="Wong S" first="Sai Wah" last="Wong">Sai Wah Wong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation></author><author><name sortKey="Wong, Bing Ou" sort="Wong, Bing Ou" uniqKey="Wong B" first="Bing-Lou" last="Wong">Bing-Lou Wong</name><affiliation><mods:affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: blwong@advantekAB. com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1160">1160</biblScope><biblScope unit="page" to="1164">1164</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK and Malden, USA</pubPlace><date type="published" when="2005-07">2005-07</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormal toxicity</term><term>Assay</term><term>Biologics</term><term>Chinese requirements</term><term>Convalescent</term><term>Convalescent plasma</term><term>Dimer</term><term>Elisa</term><term>Ethanol</term><term>Ethanol precipitation</term><term>Globulin</term><term>Heat stability</term><term>Hong kong</term><term>Human sars hyperimmune globulins</term><term>Hyperimmune</term><term>Hyperimmune globulins</term><term>Ivig</term><term>July</term><term>Neutralizing</term><term>Neutralizing antibody test</term><term>Precipitation</term><term>Respiratory syndrome</term><term>Sars</term><term>Sars antibody titer</term><term>Sars convalescent plasma</term><term>Sars hyperimmune globulins</term><term>Sars virus</term><term>Syndrome</term><term>Titer</term><term>Titer recovery</term><term>Tnbp</term><term>Transfusion</term><term>Transfusion volume</term><term>Triton</term><term>Wong</term><term>Zhang</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study. STUDY DESIGN AND METHODS: A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety. RESULTS: The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products. CONCLUSION: IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>sars</json:string><json:string>hyperimmune</json:string><json:string>convalescent</json:string><json:string>sars hyperimmune globulins</json:string><json:string>elisa</json:string><json:string>convalescent plasma</json:string><json:string>hyperimmune globulins</json:string><json:string>respiratory syndrome</json:string><json:string>neutralizing</json:string><json:string>biologics</json:string><json:string>ivig</json:string><json:string>transfusion</json:string><json:string>sars antibody titer</json:string><json:string>wong</json:string><json:string>chinese requirements</json:string><json:string>sars virus</json:string><json:string>precipitation</json:string><json:string>tnbp</json:string><json:string>hong kong</json:string><json:string>triton</json:string><json:string>zhang</json:string><json:string>titer recovery</json:string><json:string>july</json:string><json:string>globulin</json:string><json:string>assay</json:string><json:string>dimer</json:string><json:string>neutralizing antibody test</json:string><json:string>ethanol precipitation</json:string><json:string>sars convalescent plasma</json:string><json:string>ethanol</json:string><json:string>titer</json:string><json:string>transfusion volume</json:string><json:string>human sars hyperimmune globulins</json:string><json:string>abnormal toxicity</json:string><json:string>heat stability</json:string><json:string>syndrome</json:string></teeft></keywords><author><json:item><name>Zhan Zhang</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Yi‐Wu Xie</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Jiling Hong</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Xin Zhang</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Sui Yi Kwok</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Xiaowu Huang</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Sai Wah Wong</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string></affiliations></json:item><json:item><name>Bing‐Lou Wong</name><affiliations><json:string>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</json:string><json:string>E-mail: blwong@advantekAB. com</json:string></affiliations></json:item></author><articleId><json:string>TRF00179</json:string></articleId><arkIstex>ark:/67375/WNG-GXX5R0ZZ-8</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>BACKGROUND: Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study. STUDY DESIGN AND METHODS: A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety. RESULTS: The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products. CONCLUSION: IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>196</abstractWordCount><abstractCharCount>1455</abstractCharCount><keywordCount>0</keywordCount><score>6.638</score><pdfWordCount>2286</pdfWordCount><pdfCharCount>16395</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>593.583 x 783.039 pts</pdfPageSize><pdfWordsPerPage>457</pdfWordsPerPage><pdfText>true</pdfText></qualityIndicators><title>Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><pmid><json:string>15987362</json:string></pmid><corporate><json:item><name>SARSIg Group</name></json:item></corporate><genre><json:string>article</json:string></genre><host><title>Transfusion</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1537-2995</json:string></doi><issn><json:string>0041-1132</json:string></issn><eissn><json:string>1537-2995</json:string></eissn><publisherId><json:string>TRF</json:string></publisherId><volume>45</volume><issue>7</issue><pages><first>1160</first><last>1164</last><total>5</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>2005</json:string><json:string>2002</json:string></date><geogName></geogName><orgName><json:string>Pall Corp.</json:string><json:string>GBI Biotech Co.</json:string><json:string>From Shenzhen Weiwu Guangming Biological Products Co.</json:string><json:string>Department of Microvalency</json:string><json:string>American Association of Blood</json:string><json:string>US FDA</json:string><json:string>Shenzhen Weiwu Guangming Biological Products Co.</json:string><json:string>Chinese University</json:string><json:string>Department of Medicine</json:string><json:string>Chinese National Institute for the Control of Pharmaceutical</json:string><json:string>Chinese National Institute for the Control</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Yi Kwok</json:string><json:string>Gregory Cheng</json:string><json:string>Bing-Lou Wong</json:string><json:string>Yi Zhang</json:string><json:string>Hong Kong</json:string><json:string>J.S. Tam</json:string><json:string>Chan</json:string><json:string>Zhou</json:string><json:string>Zhao</json:string><json:string>Yu Chang</json:string><json:string>John S. Tam</json:string></persName><placeName><json:string>Bedford</json:string><json:string>Uppsala</json:string><json:string>NY</json:string><json:string>Beijing</json:string><json:string>East Hills</json:string><json:string>China</json:string><json:string>MA</json:string><json:string>Sweden</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-GXX5R0ZZ-8</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - cardiovascular system & hematology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1111/j.1537-2995.2005.00179.x</json:string></doi><id>A47B08754BF85061FDA2527E3FE9DDD27615D1F2</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><title level="a" type="short">PURIFICATION OF SARS HYPERIMMUNE GLOBULINS</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK and Malden, USA</pubPlace><date type="published" when="2005-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><title level="a" type="short">PURIFICATION OF SARS HYPERIMMUNE GLOBULINS</title><author xml:id="author-0000"><persName><forename type="first">Zhan</forename><surname>Zhang</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Yi‐Wu</forename><surname>Xie</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Jiling</forename><surname>Hong</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Xin</forename><surname>Zhang</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Sui Yi</forename><surname>Kwok</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Xiaowu</forename><surname>Huang</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Sai Wah</forename><surname>Wong</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0007" role="corresp"><persName><forename type="first">Bing‐Lou</forename><surname>Wong</surname></persName><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><author xml:id="author-0008"><author><orgName>SARSIg Group</orgName></author><affiliation><orgName type="laboratory">From Shenzhen Weiwu Guangming Biological Products Co. Ltd.</orgName><address><addrLine>Guangdong</addrLine><addrLine>P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</addrLine></address></affiliation></author><idno type="istex">A47B08754BF85061FDA2527E3FE9DDD27615D1F2</idno><idno type="ark">ark:/67375/WNG-GXX5R0ZZ-8</idno><idno type="DOI">10.1111/j.1537-2995.2005.00179.x</idno><idno type="unit">TRF00179</idno><idno type="toTypesetVersion">file:TRF.TRF00179.pdf</idno></analytic><monogr><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="pISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><idno type="book-DOI">10.1111/(ISSN)1537-2995</idno><idno type="book-part-DOI">10.1111/trf.2005.45.issue-7</idno><idno type="product">TRF</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1160">1160</biblScope><biblScope unit="page" to="1164">1164</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK and Malden, USA</pubPlace><date type="published" when="2005-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">BACKGROUND: </hi> Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study.</p><p><hi rend="bold">STUDY DESIGN AND METHODS: </hi> A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety.</p><p><hi rend="bold">RESULTS: </hi> The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products.</p><p><hi rend="bold">CONCLUSION: </hi> IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</p></abstract><textClass><keywords rend="tocHeading1"><term>BLOOD COMPONENTS</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Inc</publisherName><publisherLoc>Oxford, UK and Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1537-2995</doi><issn type="print">0041-1132</issn><issn type="electronic">1537-2995</issn><idGroup><id type="product" value="TRF"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="TRANSFUSION">Transfusion</title></titleGroup></publicationMeta><publicationMeta level="part" position="07007"><doi origin="wiley">10.1111/trf.2005.45.issue-7</doi><numberingGroup><numbering type="journalVolume" number="45">45</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="2005-07">July 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="19" status="forIssue"><doi origin="wiley">10.1111/j.1537-2995.2005.00179.x</doi><idGroup><id type="unit" value="TRF00179"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="tocHeading1">BLOOD COMPONENTS</title></titleGroup><eventGroup><event type="firstOnline" date="2005-06-29"></event><event type="publishedOnlineFinalForm" date="2005-06-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.4 mode:FullText source:FullText result:FullText" date="2010-03-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1160">1160</numbering><numbering type="pageLast" number="1164">1164</numbering></numberingGroup><correspondenceTo>Bing‐Lou Wong, PhD, Advantek Biologics (HK) Ltd., 3/F, HKIB, 2 Biotechnology Avenue, 12 Miles, Tai Po Road, Shatin, N.T., Hong Kong; e‐mail: <email>blwong@advantekAB. com</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:TRF.TRF00179.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received for publication November 9, 2004; revision received December 22, 2004, and accepted December 29, 2004.</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="2167"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title><title type="shortAuthors">ZHANG ET AL.</title><title type="short">PURIFICATION OF SARS HYPERIMMUNE GLOBULINS</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Zhan</givenNames><familyName>Zhang</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Yi‐Wu</givenNames><familyName>Xie</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Jiling</givenNames><familyName>Hong</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>Xin</givenNames><familyName>Zhang</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>Sui Yi</givenNames><familyName>Kwok</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Xiaowu</givenNames><familyName>Huang</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a1"><personName><givenNames>Sai Wah</givenNames><familyName>Wong</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Bing‐Lou</givenNames><familyName>Wong</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a1"><groupName>SARSIg Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>BACKGROUND: </b> Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study.</p><p><b>STUDY DESIGN AND METHODS: </b> A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety.</p><p><b>RESULTS: </b> The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products.</p><p><b>CONCLUSION: </b> IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PURIFICATION OF SARS HYPERIMMUNE GLOBULINS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma</title></titleInfo><name type="personal"><namePart type="given">Zhan</namePart><namePart type="family">Zhang</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yi‐Wu</namePart><namePart type="family">Xie</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jiling</namePart><namePart type="family">Hong</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xin</namePart><namePart type="family">Zhang</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sui Yi</namePart><namePart type="family">Kwok</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xiaowu</namePart><namePart type="family">Huang</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sai Wah</namePart><namePart type="family">Wong</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bing‐Lou</namePart><namePart type="family">Wong</namePart><affiliation>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</affiliation><affiliation>E-mail: blwong@advantekAB. com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>SARSIg Group</namePart><description>From Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, P.R. China; and Advantek Biologics (HK) Ltd., Shatin, N.T., Hong Kong.</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Inc</publisher><place><placeTerm type="text">Oxford, UK and Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2005-07</dateIssued><edition>Received for publication November 9, 2004; revision received December 22, 2004, and accepted December 29, 2004.</edition><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="formulas">0</extent><extent unit="references">16</extent><extent unit="linksCrossRef">0</extent><extent unit="words">2167</extent></physicalDescription><abstract lang="en">BACKGROUND: Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study. STUDY DESIGN AND METHODS: A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety. RESULTS: The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products. CONCLUSION: IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</abstract><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0041-1132</identifier><identifier type="eISSN">1537-2995</identifier><identifier type="DOI">10.1111/(ISSN)1537-2995</identifier><identifier type="PublisherID">TRF</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1160</start><end>1164</end><total>5</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Severe acute respiratory syndrome: clinical outcome and prognostic correlates</title></titleInfo><name type="personal"><namePart type="given">PT</namePart><namePart type="family">Tsui</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Kwok</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Yuen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Lai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsui PT, Kwok ML, Yuen H, Lai ST. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 2003;9: 1064‐9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1064</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1064</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Clinical course and management of SARS in health care workers in Toronto: a case series</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Avendano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Derkach</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Swan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Avendano M, Derkach P, Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. CMAJ 2003;168: 1649‐60.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>168</number></detail><extent unit="pages"><start>1649</start><end>60</end></extent></part><relatedItem type="host"><titleInfo><title>CMAJ</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>168</number></detail><extent unit="pages"><start>1649</start><end>60</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Interferon alfacon‐1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</title></titleInfo><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Loutfy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Blatt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KA</namePart><namePart type="family">Siminovitch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon‐1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290: 3222‐8.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>3222</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>3222</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Treatment of severe acute respiratory syndrome with convalescent plasma</title></titleInfo><name type="personal"><namePart type="given">VW</namePart><namePart type="family">Wong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Dai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AK</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Sung</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9: 199‐201.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>199</start><end>201</end></extent></part><relatedItem type="host"><titleInfo><title>Hong Kong Med J</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>199</start><end>201</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area (in Chinese)</title></titleInfo><name type="personal"><namePart type="given">XZ</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Zhao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FS</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhou XZ, Zhao M, Wang FS, et al. Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area (in Chinese). Zhonghua Yi Xue Za Zhi 2003;83: 1018‐22.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>1018</start><end>22</end></extent></part><relatedItem type="host"><titleInfo><title>Zhonghua Yi Xue Za Zhi</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>1018</start><end>22</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients</title></titleInfo><name type="personal"><namePart type="given">YO</namePart><namePart type="family">Soo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Wong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10: 676‐8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>676</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Microbiol Infect</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>676</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Mupapa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Massamba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kibadi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999;179(Suppl 1):S18 ‐S23.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>179</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>S18</start><end>‐S23</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>179</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>S18</start><end>‐S23</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Treatment of severe acute respiratory syndrome with convalescent plasma</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burnouf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Radosevich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9: 309.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>309</start></extent></part><relatedItem type="host"><titleInfo><title>Hong Kong Med J</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>309</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Treating severe acute respiratory syndrome with hyperimmune globulins</title></titleInfo><name type="personal"><namePart type="given">MB</namePart><namePart type="family">Ali</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ali MB. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J 2003;9: 391‐2.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>391</start><end>2</end></extent></part><relatedItem type="host"><titleInfo><title>Hong Kong Med J</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>391</start><end>2</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Cohn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Strong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WL</namePart><namePart type="family">Hugles</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohn EJ, Strong LE, Hugles WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68: 459‐75.</note><part><date>1946</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>459</start><end>75</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Chem Soc</title></titleInfo><part><date>1946</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>459</start><end>75</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Tri(n‐butyl)phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives</title></titleInfo><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Edwards</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MPJ</namePart><namePart type="family">Piet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Chin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Horowitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Edwards CA, Piet MPJ, Chin S, Horowitz B. Tri(n‐butyl)phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987;52: 53‐9.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>53</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>53</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Application of chromatography system in plasma protein fractionation on pilot scale</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Zhao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Zhong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Biotechnology of blood proteins</title></titleInfo><originInfo><publisher>Colloque INSERM/John Libbey Eurotext Ltd.;</publisher></originInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>227</number></detail><extent unit="pages"><start>137</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Immunofluorescence assay for serologic diagnosis of SARS</title></titleInfo><name type="personal"><namePart type="given">PK</namePart><namePart type="family">Chan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KC</namePart><namePart type="family">Ng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Chan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chan PK, Ng KC, Chan RC, et al. Immunofluorescence assay for serologic diagnosis of SARS. Emerg Infect Dis 2004;10: 530‐2.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>530</start><end>2</end></extent></part><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>530</start><end>2</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>A real‐time PCR for SARS‐coronavirus incorporating target gene pre‐amplification</title></titleInfo><name type="personal"><namePart type="given">LT</namePart><namePart type="family">Lau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YW</namePart><namePart type="family">Fung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FP</namePart><namePart type="family">Wong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lau LT, Fung YW, Wong FP, et al. A real‐time PCR for SARS‐coronavirus incorporating target gene pre‐amplification. Biochem Biophys Res Commun 2003;312: 1290‐6.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>312</number></detail><extent unit="pages"><start>1290</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem Biophys Res Commun</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>312</number></detail><extent unit="pages"><start>1290</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>A novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Ksiazek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Erdman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CS</namePart><namePart type="family">Goldsmith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348: 1953‐66.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Clinical progression and viral load in a community outbreak of coronavirus‐associated SARS pneumonia: a prospective study</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Peiris</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Chu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VC</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus‐associated SARS pneumonia: a prospective study. Lancet 2003;361: 1767‐72.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1767</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1767</start><end>72</end></extent></part></relatedItem></relatedItem><identifier type="istex">A47B08754BF85061FDA2527E3FE9DDD27615D1F2</identifier><identifier type="ark">ark:/67375/WNG-GXX5R0ZZ-8</identifier><identifier type="DOI">10.1111/j.1537-2995.2005.00179.x</identifier><identifier type="ArticleID">TRF00179</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-GXX5R0ZZ-8/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000133 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000133 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A47B08754BF85061FDA2527E3FE9DDD27615D1F2
|texte= Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
}}
| This area was generated with Dilib version V0.6.33. |  |